

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

scr.zacks.com

Brad Sorensen

312-265-9574

bsorensen@zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Revelation Bios

(REVB-NASDAQ)

REVB: 2026 Looks to be Good Year

Revelation Biosciences is a life sciences company whose focus is the development of immunologic-based therapies. We value REVB at \$22.50 using the comparable method involving companies with similar characteristics.

Current Price (01/15/26)	\$0.90
Valuation	\$22.50

SUMMARY DATA

52-Week High	\$23.52
52-Week Low	\$0.80
One-Year Return (%)	-95.48
Beta	-0.14
Average Daily Volume (sh)	89,457
Shares Outstanding (mil)	3
Market Capitalization (\$mil)	\$3
Short Interest Ratio (days)	N/A
Institutional Ownership (%)	13
Insider Ownership (%)	14
Annual Cash Dividend	\$0.00
Dividend Yield (%)	0.00
5-Yr. Historical Growth Rates	
Sales (%)	N/A
Earnings Per Share (%)	N/A
Dividend (%)	N/A

OUTLOOK

Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.

The company begins the year with outstanding test results, preparing for an FDA decision, presenting its results before a prestigious group and preparing for commercialization. We believe investors should look at the stock now as we approach an inflection point.

ZACKS ESTIMATES

	Revenue (in millions of \$)				
	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	0 A	0 A	0 A	0 A	0 A
2024	0 A	0 A	0 A	0 A	0 A
2025	0 A	0 A	0 A	0 E	0 E
2026	0 E	0 E	0 E	0 E	0 E

	Earnings Per Share				
	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	1.96 A	-0.25 A	-0.26 A	-8.33 A	-10.80 A
2024	-2.46A	-5.13A	-0.84A	-10.06A	-18.49A
2025	-2.11A	-7.01A	-1.77A	-1.50E	-12.39E
2026	-1.40E	-1.35E	-1.25E	-1.09E	-5.09E

*numbers don't add due to reverse stock split

Update

Revelation Biosciences (REVB) begins 2026 with great momentum and making decisions that put commercialization of its important treatment in reach. We believe this year will be a transformational one for the company and suggest investors take a look at REVB before the inflection point we believe is coming.

Gemini is the company's primary treatment and is an intravenously administered treatment that reduces the damage associated with inflammation, which could be used in treating numerous conditions. Gemini is currently in a Phase 1b trial for chronic kidney disease (CKD), which approximately 37 million people are afflicted with. The company recently released data from its Phase 1 PRIME clinical study in stage 3 and 4 CKD patients. The primary endpoint to evaluate safety and tolerability of escalating doses was met.

But the major news was that Gemini reduced inflammatory activity and restored normal cellular response. This demonstrates Gemini's ability to durably rebalance the inflammatory process at the cellular level. This has implications for dozens of afflictions such as CKD and burns and makes the process toward commercialization more likely in our view. The statement from the Principal Investigator made us take additional notice as it was more positive than what we have often seen. Dr. Pablo Pergola, Research Director at Clinical Advancement Center, PLLC., noted, "**The activity observed with a single dose of Gemini in patients is shocking.** This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation."

Specifically, test results showed that in patients with high background PBMC activity, which are immune cells and can help be a measure of inflammation, Gemini significantly reduced inflammation relative to placebo patient PBMCs post dose and remained significantly below their baseline value through 7 days. Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects. The importance of this cannot be overstated, Gemini is changing the cells and returning them to a normal state from the inflamed state, which treats the patient durably instead of just masking the symptoms. This ability has the potential to positively affect millions of patients suffering from CKD and other inflammatory diseases in a way that has been impossible to this point.


Earlier this year, the company announced that it is starting the GMP manufacturing of Gemini and the placebo. We view this as a very positive step that shows management's confidence in the need for more product for later-stage testing and will avoid delays as those tests begin. Additionally, the company announced that it is presenting the above referenced results to The International Conference on Advances in Critical Care Nephrology—another indication of the traction that REVB is getting.

We are under no illusions that it's easy to bring new therapies all the way to commercialization but view these results as a significant step forward to that goal. As a result, we recently raised our price target on REVB to \$22.50 per share and urge investors to use this groundbreaking news to consider investing in REVB.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Revelation Income Statement and Balance Sheet										
	1Q2024A	2Q2024A	3Q2024A	4Q2024A	1Q2025A	2Q2025A	3Q2025A	4Q2025E	2026E	2027E
Revenues	0	0	0	0	0	0	0	0	0	0
Operating Expenses										
Research and Development	717,582	1,394,929	830,981	605,504	858,830	1,317,980	922,857	941,314	3,765,257	3,840,562
General and Administrative	1,184,556	1,127,468	965,705	1,148,384	1,236,157	1,143,249	1,020,154	1,040,557	4,162,228	4,245,473
Total Operating Expenses	1,902,138	2,522,397	1,796,686	1,753,888	2,094,987	2,461,229	1,943,011	1,981,871	7,927,485	8,086,035
Gain/(Loss) from Operations	(1,902,138)	(2,522,397)	(1,796,686)	(1,753,888)	(2,094,987)	(2,461,229)	(1,943,011)	(1,981,871)	(7,927,485)	(8,086,035)
Other Income/(Expense)										
Change in fv of warrant liab.	68,427	4,416	6,041	2,557	1,417	44	611	623	2,493	2,543
Other income/(expense)	(847,722)	(5,871,838)	(450,920)	25,612	42,285	16,803	35,224	35,928	143,714	146,588
Total other income/(expense)	(779,295)	(5,867,422)	(444,879)	28,169	43,702	16,847	35,835	36,552	146,207	149,131
Net Income/(Loss)	(2,681,433)	(8,389,819)	(2,241,565)	(1,725,719)	(2,051,285)	(2,444,382)	(1,907,176)	(1,945,320)	(7,781,278)	(7,936,904)
Deemed Dividends	0	0	0	0	0	(3,181,786)	(2,769,742)	(2,215,794)	(7,755,278)	(6,979,750)
Net loss attributable to Common S/H	(2,681,433)	(8,389,819)	(2,241,565)	(1,725,719)	(2,051,285)	(5,626,168)	(4,676,918)	(4,161,113)	(15,536,556)	(14,916,653)
Net Income/(Loss) per share	(\$2.46)	(\$5.13)	(\$0.84)	(\$10.06)	(\$2.11)	(\$7.01)	(\$1.77)	(\$1.50)	(\$5.09)	(\$4.65)
Shares Outstanding-diluted	1,089,833	1,635,234	2,679,941	171,510	971,313	802,670	2,644,733	2,776,970	3,054,667	3,207,400
Assets										
Current Assets:										
Cash and equivalents	14,551,740	12,073,058	6,541,052	6,499,018	3,704,611	5,173,871	12,708,489	12,073,065	6,036,532	3,018,266
Other current assets	71,876	125,743	117,846	66,699	223,270	186,049	123,934	127,652	131,482	135,426
Total current assets	14,623,616	12,198,801	6,658,898	6,565,717	3,927,881	5,359,920	12,832,423	12,200,717	6,168,014	3,153,692
Property and Equipment	77,994	70,774	81,242	56,332	42,390	35,170	23,919	42,393	42,394	42,395
Total Assets	14,701,610	12,269,575	6,740,140	6,622,049	3,970,271	5,395,090	12,856,342	12,243,110	6,210,408	3,196,087
Liabilities and SH Equity										
Current Liabilities:										
Accounts payable	1,681,665	1,281,323	3,127,348	783,621	625,058	828,894	1,034,951	1,055,650	1,076,763	1,098,298
Accrued expenses	620,280	8,454,139	934,372	1,127,800	463,632	739,626	819,381	835,769	852,484	869,534
Def. underwriting coms.	2,911,260	1,382,848	0	0	0	-	-	-	-	-
Warrant liabilities	15,260	10,844	4,803	2,246	829	786	175	179	182	186
Total current liabilities	5,228,465	11,129,154	4,066,523	1,913,667	1,089,519	1,569,306	1,854,507	1,891,597	1,929,429	1,968,018
Total Liabilities	5,228,465	11,129,154	4,066,523	1,913,667	1,089,519	1,569,306	1,854,507	1,891,597	1,929,429	1,968,018
Shareholder Equity										
Common Stock	1,633	1,643	4,292	522	964	1,535	3,586	1,535	1,535	1,535
Additional Paid-in Capital	37,620,047	37,677,132	41,449,244	45,213,498	45,436,511	48,825,354	57,906,530	58,485,596	59,070,452	62,023,974
Accumulated Deficit	(28,148,535)	(36,538,354)	(38,779,919)	(40,505,638)	(42,556,723)	(45,001,105)	(46,908,281)	(48,135,618)	(54,791,008)	(60,797,440)
Total Shareholder Equity	9,473,145	1,140,421	2,673,617	4,708,382	2,880,752	3,825,784	11,001,835	10,351,513	4,280,979	1,228,069
Total Liabilities and SE	14,701,610	12,269,575	6,740,140	6,622,049	3,970,271	5,395,090	12,856,342	12,243,110	6,210,408	3,196,087

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.